ATTR Epidemiology, Genetics, and Prognostic Factors

Chukwuemeka A. Obi; William C. Mostertz; Jan M. Griffin; Daniel P. Judge

doi:10.14797/mdcvj.1066

ATTR Epidemiology, Genetics, and Prognostic Factors

Methodist DeBakey Cardiovascular Journal

Volume 18 (2022): Issue 2

By: Chukwuemeka A. Obi , William C. Mostertz , Jan M. Griffin and Daniel P. Judge

Open Access

|Mar 2022

Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016 Jun 25;387(10038):2641-2654. doi: 10.1016/S0140-6736(15)01274-X
Open DOI Search in Google Scholar Back to article
Kristen AV, Ajroud-Driss S, Conceição I, et al. Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegener Dis Manag. 2019 Feb;9(1):5-23. doi: 10.2217/nmt-2018-0033
Open DOI Search in Google Scholar Back to article
Finsterer J, Iglseder S, Wanschitz J, et al. Hereditary transthyretin-related amyloidosis. Acta Neurol Scand. 2019 Feb;139(2):92-105. doi: 10.1111/ane.13035
Open DOI Search in Google Scholar Back to article
Manolis AS, Manolis AA, Manolis TA, Melita H. Cardiac amyloidosis: An underdiagnosed/underappreciated disease. Eur J Intern Med. 2019 Sep;67:1-13. doi: 10.1016/j.ejim.2019.07.022
Open DOI Search in Google Scholar Back to article
Yamamoto H, Yokochi T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Fail. 2019 Dec;6(6):1128-1139. doi: 10.1002/ehf2.12518
Open DOI Search in Google Scholar Back to article
Coelho T, Maurer MS, Suhr OB. THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013 Jan;29(1):63-76. doi: 10.1185/03007995.2012.754348
Open DOI Search in Google Scholar Back to article
Stakos DA, Stamatelopoulos K, Bampatsias D, et al. The Alzheimer’s Disease Amyloid-Beta Hypothesis in Cardiovascular Aging and Disease: JACC Focus Seminar. J Am Coll Cardiol. 2020 Mar 3;75(8):952-967. doi: 10.1016/j.jacc.2019.12.033
Open DOI Search in Google Scholar Back to article
Coelho T, Merlini G, Bulawa CE, et al. Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. Neurol Ther. 2016 Jun;5(1):1-25. doi: 10.1007/s40120-016-0040-x
Open DOI Search in Google Scholar Back to article
Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017 Apr 4;135(14):1357-1377. doi: 10.1161/CIRCULATIONAHA.116.024438
Open DOI Search in Google Scholar Back to article
Rapezzi C, Lorenzini M, Longhi S, et al. Cardiac amyloidosis: the great pretender. Heart Fail Rev. 2015 Mar;20(2):117-24. doi: 10.1007/s10741-015-9480-0
Open DOI Search in Google Scholar Back to article
Palladini G, Merlini G. Systemic amyloidoses: what an internist should know. Eur J Intern Med. 2013 Dec;24(8):729-39. doi: 10.1016/j.ejim.2013.10.007
Open DOI Search in Google Scholar Back to article
Lauppe RE, Hansen JL, Gerdesköld C, et al. Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden. Open Heart. 2021 Oct;8(2):e001755. doi: 10.1136/openhrt-2021-001755
Open DOI Search in Google Scholar Back to article
Porcari A, Merlo M, Rapezzi C, Sinagra G. Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery. Eur J Intern Med. 2020 Dec;82:7-15. doi: 10.1016/j.ejim.2020.09.025
Open DOI Search in Google Scholar Back to article
Grogan M, Scott CG, Kyle RA, et al. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. J Am Coll Cardiol. 2016 Sep 6;68(10):1014-20. doi: 10.1016/j.jacc.2016.06.033
Open DOI Search in Google Scholar Back to article
Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010 Jul;7(7):398-408. doi: 10.1038/nrcardio.2010.67
Open DOI Search in Google Scholar Back to article
Castaño A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017 Oct 7;38(38):2879-2887. doi: 10.1093/eurheartj/ehx350
Open DOI Search in Google Scholar Back to article
Papoutsidakis N, Miller EJ, Rodonski A, Jacoby D. Time Course of Common Clinical Manifestations in Patients with Transthyretin Cardiac Amyloidosis: Delay From Symptom Onset to Diagnosis. J Card Fail. 2018 Feb;24(2):131-133. doi: 10.1016/j.cardfail.2017.12.005
Open DOI Search in Google Scholar Back to article
Tanskanen M, Peuralinna T, Polvikoski T, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40(3):232-9. doi: 10.1080/07853890701842988
Open DOI Search in Google Scholar Back to article
Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation. 2020 Mar 3;141(9):e139-596. doi: 10.1161/CIR.0000000000000757
Open DOI Search in Google Scholar Back to article
Mohammed SF, Mirzoyev SA, Edwards WD, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2014 Apr;2(2):113-22. doi: 10.1016/j.jchf.2013.11.004
Open DOI Search in Google Scholar Back to article
Roger VL. Epidemiology of Heart Failure: A Contemporary Perspective. Circ Res. 2021 May 14;128(10):1421-1434. doi: 10.1161/CIRCRESAHA.121.318172
Open DOI Search in Google Scholar Back to article
Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012 Sep 4;126(10):1286-300. doi: 10.1161/CIRCULATIONAHA.111.078915
Open DOI Search in Google Scholar Back to article
Dwulet FE, Benson MD. Primary structure of an amyloid prealbumin and its plasma precursor in a heredofamilial polyneuropathy of Swedish origin. Proc Natl Acad Sci U S A. 1984 Feb;81(3):694-8. doi: 10.1073/pnas.81.3.694
Open DOI Search in Google Scholar Back to article
Tsuzuki T, Mita S, Araki S, Shimada K. Structure of the human prealbumin gene. J Biol Chem. 1985 Oct 5;260(22):12224-7. doi: 10.1016/S0021-9258(17)39013-0
Open DOI Search in Google Scholar Back to article
Conceição I, Damy T, Romero M, et al. Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. Amyloid. 2019 Mar;26(1):3-9. doi: 10.1080/13506129.2018.1556156
Open DOI Search in Google Scholar Back to article
Brown EE, Fajardo J, Judge DP. Positive family history decreases diagnosis time by over 200. Amyloid. 2019;26(sup1):17. doi: 10.1080/13506129.2019.1582484
Open DOI Search in Google Scholar Back to article
Maurer MS, Hanna M, Grogan M, et al. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016 Jul 12;68(2):161-72. doi: 10.1016/j.jacc.2016.03.596
Open DOI Search in Google Scholar Back to article
Jacobson DR, Alexander AA, Tagoe C, Buxbaum JN. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans. Amyloid. 2015;22(3):171-4. doi: 10.3109/13506129.2015.1051219
Open DOI Search in Google Scholar Back to article
Kirov A, Sarafov S, Pavlova Z, et al. Founder effect of the Glu89Gln TTR mutation in the Bulgarian population. Amyloid. 2019 Dec;26(4):181-185. doi: 10.1080/13506129.2019.1634539
Open DOI Search in Google Scholar Back to article
Damy T, Kristen AV, Suhr OB, et al. Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS). Eur Heart J. 2019 Apr 1;ehz173. doi: 10.1093/eurheartj/ehz173
Open DOI Search in Google Scholar Back to article
Sattianayagam PT, Hahn AF, Whelan CJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J. 2012 May;33(9):1120-7. doi: 10.1093/eurheartj/ehr383
Open DOI Search in Google Scholar Back to article
Reilly MM, Staunton H, Harding AE. Familial amyloid polyneuropathy (TTR ala 60) in north west Ireland: a clinical, genetic, and epidemiological study. J Neurol Neurosurg Psychiatry. 1995 Jul;59(1):45-9. doi: 10.1136/jnnp.59.1.45
Open DOI Search in Google Scholar Back to article
Buxbaum JN, Ruberg FL. Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. Genet Med. 2017 Jul;19(7):733-742. doi: 10.1038/gim.2016.200
Open DOI Search in Google Scholar Back to article
Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013 Feb 20;8:31. doi: 10.1186/1750-1172-8-31
Open DOI Search in Google Scholar Back to article
Uemichi T, Uitti RJ, Koeppen AH, Donat JR, Benson MD. Oculoleptomeningeal amyloidosis associated with a new transthyretin variant Ser64. Arch Neurol. 1999 Sep;56(9):1152-5. doi: 10.1001/archneur.56.9.1152
Open DOI Search in Google Scholar Back to article
Trachtenberg BH, Shah SK, Nussbaum RL, Bristow SL, Malladi R, Vatta M. Presence of the V122I Variant of Hereditary Transthyretin-Mediated Amyloidosis Among Self-Reported White Individuals in a Sponsored Genetic Testing Program. Circ Genom Precis Med. 2021 Oct;14(5):e003466. doi: 10.1161/CIRCGEN.121.003466
Open DOI Search in Google Scholar Back to article
Parman Y, Adams D, Obici L, et al.; European Network for TTR-FAP (ATTReuNET). Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. Curr Opin Neurol. 2016 Feb;29 Suppl 1(Suppl 1):S3-S13. doi: 10.1097/WCO.0000000000000288
Open DOI Search in Google Scholar Back to article
Bonaïti B, Alarcon F, Bonaïti-Pellié C, Planté-Bordeneuve V. Parent-of-origin effect in transthyretin related amyloid polyneuropathy. Amyloid. 2009;16(3):149-50. doi: 10.1080/13506120903093944
Open DOI Search in Google Scholar Back to article
Cuddy SAM, Falk RH. Amyloidosis as a Systemic Disease in Context. Can J Cardiol. 2020 Mar;36(3):396-407. doi: 10.1016/j.cjca.2019.12.033
Open DOI Search in Google Scholar Back to article
Vio R, Angelini A, Basso C, et al. Hypertrophic Cardiomyopathy and Primary Restrictive Cardiomyopathy: Similarities, Differences and Phenocopies. 2021 May 1;10(9):1954. doi: 10.3390/jcm10091954
Open DOI Search in Google Scholar Back to article
Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017 Jun;23(7 Suppl):S107-S112
Search in Google Scholar Back to article
Judge DP, Heitner SB, Falk RH, et al. Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol. 2019 Jul 23;74(3):285-295. doi: 10.1016/j.jacc.2019.03.012
Open DOI Search in Google Scholar Back to article
González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015 Oct 7;36(38):2585-94. doi: 10.1093/eurheartj/ehv338
Open DOI Search in Google Scholar Back to article
Oerlemans MIFJ, Rutten KHG, Minnema MC, Raymakers RAP, Asselbergs FW, de Jonge N. Cardiac amyloidosis: the need for early diagnosis. Neth Heart J. 2019 Nov;27(11):525-536. doi: 10.1007/s12471-019-1299-1
Open DOI Search in Google Scholar Back to article
Alexander KM, Maurer MS, Fergus IV. Cardiac Amyloid Heart Disease in Racial/Ethnic Minorities: Focus on Transthyretin Amyloid Cardiomyopathy. In: Ferdinand KC, Taylor HA Jr. Rodriguez CJ, editors. Cardiovascular Disease in Racial and Ethnic Minority Populations. New York, NY: Springer International Publishing; 2021. p. 201-215. doi: 10.1007/978-3-030-81034-4_17
Open DOI Search in Google Scholar Back to article
Schwartzlow C, Kazamel M. Hereditary Transthyretin Amyloidosis: Clinical Presentation and Management Updates. J Clin Neuromuscul Dis. 2020 Mar;21(3):144-156. doi: 10.1097/CND.0000000000000270
Open DOI Search in Google Scholar Back to article
Manganelli F, Fabrizi GM, Luigetti M, Mandich P, Mazzeo A, Pareyson D. Hereditary transthyretin amyloidosis overview. Neurol Sci. 2020 Nov 14. doi: 10.1007/s10072-020-04889-2
Open DOI Search in Google Scholar Back to article
Holmgren G, Costa PM, Andersson C, et al. Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet. 1994 May;31(5):351-4. doi: 10.1136/jmg.31.5.351
Open DOI Search in Google Scholar Back to article
Hellman U, Alarcon F, Lundgren H-E, Suhr OB, Bonaiti-Pellié C, Planté-Bordeneuve V. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid. 2008 Sep;15(3):181-6. doi: 10.1080/13506120802193720
Open DOI Search in Google Scholar Back to article
Conceição I. Clinical features of TTR-FAP in Portugal. Amyloid. 2012 Jun;19 Suppl 1:71-2. doi: 10.3109/13506129.2012.673184
Open DOI Search in Google Scholar Back to article
Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med. 1997 Feb 13;336(7):466-73. doi: 10.1056/NEJM199702133360703
Open DOI Search in Google Scholar Back to article
Soares ML, Coelho T, Sousa A, et al. Haplotypes and DNA sequence variation within and surrounding the transthyretin gene: genotype-phenotype correlations in familial amyloid polyneuropathy (V30M) in Portugal and Sweden. Eur J Hum Genet. 2004 Mar;12(3):225-37. doi: 10.1038/sj.ejhg.5201095
Open DOI Search in Google Scholar Back to article
Rapezzi C, Riva L, Quarta CC, et al. Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid. 2008 Mar;15(1):40-8. doi: 10.1080/13506120701815373
Open DOI Search in Google Scholar Back to article
Liang D. The potency of AG10 in stabilizing transthyretin is driven by interactions mimicking the disease-suppressing T119M variant [dissertation]. Stockton, California: University of the Pacific; 2019. 57 p.
Search in Google Scholar Back to article
Hammarström P, Schneider F, Kelly JW. Trans-suppression of misfolding in an amyloid disease. Science. 2001 Sep 28;293(5539):2459-62. doi: 10.1126/science.1062245
Open DOI Search in Google Scholar Back to article
Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018 Aug 7;39(30):2799-2806. doi: 10.1093/eurheartj/ehx589
Open DOI Search in Google Scholar Back to article
Cheng RK, Levy WC, Vasbinder A, et al. Diuretic Dose and NYHA Functional Class Are Independent Predictors of Mortality in Patients With Transthyretin Cardiac Amyloidosis. JACC CardioOncol. 2020 Sep;2(3):414-424. doi: 10.1016/j.jaccao.2020.06.007
Open DOI Search in Google Scholar Back to article
Myhre PL, Vaduganathan M, Claggett B, et al. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial. J Am Coll Cardiol. 2019 Mar 26;73(11):1264-1272. doi: 10.1016/j.jacc.2019.01.018
Open DOI Search in Google Scholar Back to article
Pinney JH, Whelan CJ, Petrie A, et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc. 2013 Apr 22;2(2):e000098. doi: 10.1161/JAHA.113.000098
Open DOI Search in Google Scholar Back to article
Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009 Sep 29;120(13):1203-12. doi: 10.1161/CIRCULATIONAHA.108.843334
Open DOI Search in Google Scholar Back to article
Galat A, Rosso J, Guellich A, et al. Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis. Amyloid. 2015;22(4):210-20. doi: 10.3109/13506129.2015.1072089
Open DOI Search in Google Scholar Back to article
Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689
Open DOI Search in Google Scholar Back to article
Sanchis K, Cariou E, Colombat M, et al. Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality. Amyloid. 2019 Sep;26(3):128-138. doi: 10.1080/13506129.2019.1620724
Open DOI Search in Google Scholar Back to article
Longhi S, Quarta CC, Milandri A, et al. Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role. Amyloid. 2015;22(3):147-55. doi: 10.3109/13506129.2015.1028616
Open DOI Search in Google Scholar Back to article
Mints YY, Doros G, Berk JL, Connors LH, Ruberg FL. Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience. ESC Heart Fail. 2018 Oct;5(5):772-779. doi: 10.1002/ehf2.12308
Open DOI Search in Google Scholar Back to article
Feng DaLi, Edwards WD, Oh JK, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation. 2007 Nov 20;116(21):2420-6. doi: 10.1161/CIRCULATIONAHA.107.697763
Open DOI Search in Google Scholar Back to article
El-Am EA, Dispenzieri A, Melduni RM, et al. Direct Current Cardioversion of Atrial Arrhythmias in Adults With Cardiac Amyloidosis. J Am Coll Cardiol. 2019 Feb 12;73(5):589-597. doi: 10.1016/j.jacc.2018.10.079
Open DOI Search in Google Scholar Back to article
Donnellan E, Elshazly MB, Vakamudi S, et al. No Association Between CHADS-VASc Score and Left Atrial Appendage Thrombus in Patients With Transthyretin Amyloidosis. JACC Clin Electrophysiol. 2019 Dec;5(12):1473-1474. doi: 10.1016/j.jacep.2019.10.013
Open DOI Search in Google Scholar Back to article
Donnellan E, Wazni OM, Saliba WI, et al. Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality. J Cardiovasc Electrophysiol. 2019 Nov;30(11):2427-2432. doi: 10.1111/jce.14180
Open DOI Search in Google Scholar Back to article
Donnellan E, Wazni OM, Hanna M, Kanj M, Saliba WI, Jaber WA. Cardiac Resynchronization Therapy for Transthyretin Cardiac Amyloidosis. J Am Heart Assoc. 2020 Jul 21;9(14):e017335. doi: 10.1161/JAHA.120.017335
Open DOI Search in Google Scholar Back to article
Giancaterino S, Urey MA, Darden D, Hsu JC. Management of Arrhythmias in Cardiac Amyloidosis. JACC Clin Electrophysiol. 2020 Apr;6(4):351-361. doi: 10.1016/j.jacep.2020.01.004
Open DOI Search in Google Scholar Back to article
Lane T, Fontana M, Martinez-Naharro A, et al. Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. Circulation. 2019 Jul 2;140(1):16-26. doi: 10.1161/CIRCULATIONAHA.118.038169
Open DOI Search in Google Scholar Back to article
Coelho T, Maia LF, da Silva AM, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012 Aug 21;79(8):785-92. doi: 10.1212/WNL.0b013e3182661eb1
Open DOI Search in Google Scholar Back to article
Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):11-21. doi: 10.1056/NEJMoa1716153
Open DOI Search in Google Scholar Back to article
Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):22-31. doi: 10.1056/NEJMoa1716793
Open DOI Search in Google Scholar Back to article

Authors

Metrics

Articles in this issue

DOI: https://doi.org/10.14797/mdcvj.1066 | Journal eISSN: 1947-6108

Journal RSS Feed

Language: English

Page range: 17 - 26

Submitted on: Nov 19, 2021

Accepted on: Dec 23, 2021

Published on: Mar 14, 2022

Published by: Houston Methodist DeBakey Heart & Vascular Center

In partnership with: Paradigm Publishing Services

Keywords:

© 2022 Chukwuemeka A. Obi, William C. Mostertz, Jan M. Griffin, Daniel P. Judge, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.

Volume 18 (2022): Issue 2